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Non-alcoholic fatty liver disease (NAFLD) is the most common 
cause of chronic liver disease in the world,1-3 affecting about a third 
of the USA’s population.4 Non-alcoholic steatohepatitis (NASH) is 
the non-benign form of NAFLD potentially leading to liver cirrhosis 
but also to hepatocellular carcinoma.5,6 There is no difference in the 
management of patients with NASH with minimal forms of fibrosis 
and without fibrosis. However, patients with NASH and advanced 
forms of fibrosis must be identified as they will require more intensive 
management. The assessment of patients with NAFLD/NASH for 
advanced disease by liver biopsy is regarded as the gold standard.4 
However, a liver biopsy sampling error can result in substantial 
misdiagnosis and staging inaccuracies.7 The main concern regarding 
liver biopsies is the lack of resources, largely because of the large 
number of subjects affected by NAFLD. Secondly, approximately 60 
- 90% of NAFLD-affected subjects have a benign form of the disease 
not requiring biopsy.8-10 Furthermore, liver biopsy is invasive with 
potential complications.11
Aminotransferase levels do not correlate with underlying biological 
activity and can even be normal in advanced disease.12-14 An aspartate 
aminotransferase-to-alanine aminotransferase (AST/ALT) ratio of 
more than 1 may suggest advanced fibrosis or cirrhosis.15 Numerous 
test panels have been developed for non-invasive tests to diagnose 
advanced liver disease,16 only 4 of which have been evaluated in 
NAFLD.4 The group that investigated the BAAT (BMI, ALT, age, 
triglycerides) score replaced this test by the FibroTest.17 The FibroTest 
combines 5 biochemical markers, namely β2-macroglobulin, 
apolipoprotein A1, haptoglobulin, total bilirubin and gamma-
glutamyl transpeptidase (GGT). Age and sex, together with the 
aforementioned markers, are entered into a computer programme 
using an undisclosed formula. The area under curve (AUC) for the 
FibroTest as predictive of advanced fibrosis is 0.87. Unfortunately, the 
FibroTest is expensive and not widely available. The European Liver 
Fibrosis (ELF) Study Group examined a panel of extracellular matrix 
(ECM)-related components from which an algorithm was developed 
with an AUC for severe fibrosis of 0.87.18 This panel is also not readily 
available and will be expensive, especially in developing countries.
The NASH fibrosis score (NFS) is an algorithm of 6 readily available 
laboratory and clinical variables including age, hyperglycaemia, BMI, 
platelet count, albumin, and AST/ALT ratio.19 By applying this 
model, 75% of 733 patients in this study avoided liver biopsy. Guha 
et al.20 determined that the addition of established simple markers 
to the ELF panel augmented the diagnostic performance and that 
liver biopsy could be avoided in 88% of cases. Wai et al. validated 
the aspartate aminotransferase-to-platelet ratio index (APRI) score 
in patients with hepatitis C.21 APRI is a simple calculation of two 
laboratory variables, namely AST and platelets. This score can easily 
be used at the bedside or in an outpatient setting. APRI has not been 
validated for use in NAFLD/NASH and has not been compared with 
other non-invasive markers for advanced fibrosis in NAFLD/NASH.
We therefore aimed to validate APRI as a non-invasive marker of 
advanced fibrosis in subjects with NAFLD. Furthermore, by proving 
superior sensitivity and specificity of APRI compared with AST/
ALT ratio and comparable sensitivity and specificity to NFS, APRI Corresponding author: F Kruger (ckruger@gastrosa.com)
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Background. Non-alcoholic steatohepatitis (NASH) can lead 
to cirrhosis and hepatocellular carcinoma. The NASH fibrosis 
score (NFS) has proven to be a reliable, non-invasive marker for 
prediction of advanced fibrosis. Aspartate aminotransferase-to-
platelet ratio index (APRI) is a simpler calculation than NFS, but 
has never been studied in patients with non-alcoholic fatty liver 
disease (NAFLD).
Aim. To validate APRI as a non-invasive marker of liver fibrosis 
in subjects with NAFLD to be used in clinical practice.
Design/Methods. The cohort consisted of 111 patients with 
histological diagnoses of NAFLD. The biopsy samples were staged 
and graded according to the NASH clinical research network 
(CRN) criteria. These were grouped into fatty liver disease (FLD), 
NASH, no/mild fibrosis, and advanced fibrosis. The sensitivity 
and specificity of APRI were compared with NFS and aspartate 
aminotransferase-to-alanine aminotransferase (AST/ALT) ratio.
Results. The APRI was significantly higher in the advanced 
fibrosis group. The area under receiver operating characteristic 
(ROC) curve for APRI was 0.85 with an optimal cut-off of 0.98, 
giving a sensitivity of 75% and a specificity of 86%. The NFS was 
significantly lower in the advanced fibrosis group. The ROC for 
NFS gave an area under curve (AUC) of 0.77 and a cut-off value of 
-1.3 with a sensitivity of 76% and specificity of 69%. The positive 
predictive value for APRI was 54% as opposed to 34% for NFS. The 
negative predictive value was 93% for APRI and 94% for NFS.
Conclusion. APRI compared favourably to NFS and was superior 
to AST/ALT for the prediction of advanced fibrosis. We therefore 
propose the use of APRI in a new algorithm for the detection of 
advanced fibrosis.
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can be used as part of a proposed simple, user-friendly and reliable 
algorithm to predict advanced fibrosis in subjects with NAFLD, 
thereby avoiding liver biopsies for patients with no or minimal 
fibrosis.
Methods
Patients
The study included 111 patients with histologically confirmed 
NAFLD recruited from 3 sites in the Western Cape province of South 
Africa, i.e. Tygerberg Academic Hospital, and Louis Leipoldt and 
Durbanville Medi-Clinics. The study was approved by the regulatory 
body of Stellenbosch University. Patient age, sex, body mass index 
(BMI), history of diabetes and detailed alcohol consumption history 
were recorded. Patients who consumed more than 140 g of alcohol 
per week were excluded. Other liver diseases were also excluded. 
Clinical and laboratory data were collected either before or on the 
day of the liver biopsy. BMI was calculated using the formula: weight 
in kg/height in metres2.
Biochemistry
Laboratory evaluation included full liver function tests, full blood 
count, fasting glucose and fasting insulin. Insulin resistance was 
determined by using the homoeostasis model assessment (HOMA) 
formula = insulin x glucose/22.5. APRI was calculated by using the 
formula: (AST/upper limit of normal x 100)/platelet count. NFS by 
Angulo et al.: 1.675 + 0.037 x age (years) + 0.094 x BMI (kg/m2) + 
1.13 x IFG/diabetes (yes=1, no=0) + 0.99 x AST/ALT ratio – 0.013 x 
platelets (x 109/l) – 0.66 x albumin (g/dl).
Histology
The same two pathologists reported on each sample that were 
specially stained to exclude iron and copper overload. These were 
staged and graded according to the NASH National Institute of Health 
Chronic Research Network criteria. The samples were classified into 
four histologically defined groups, i.e. fatty liver disease not fulfilling 
the criteria for NASH (FLD), NASH, no or mild fibrosis (stage 1 
and 2) and advanced fibrosis (stage 3 and 4). ALT, AST/ALT ratio, 
APRI and NFS were performed for each group, and compared for 
predictiveness of advanced NAFLD.
Statistical analysis
One-way ANOVA was used to compare average measurements 
between different groups of patients. Possible deviations from the 
assumptions were checked and highlighted in cases where they 
caused a problem. The non-parametric Mann-Whitney U-test was 
then used. Receiver operating characteristic (ROC) analysis was used 
to determine optimal cut-off points for diagnosis. AUC, sensitivity, 
specificity, positive predictive value (ppv) and negative predictive 
value (npv) were reported.
Results
Patient demographics
Our subjects were ethnically classified as: 69% coloured, 25% white, 
5% black and 1% Indian; 73% were female. The mean age of the 
cohort was 52 years (confidence interval (CI) 50 - 54 yrs); mean 
BMI was 35 (CI 34 - 36); and 43% were type II diabetics. The mean 
homeostasis model of assessment – insulin resistance (HOMA-IR) 
of the non-diabetic patients was 7 (CI 4 - 9), 41% of the patients had 
NASH, and 17% had advanced fibrosis. None had decompensated 
liver disease.
The mean AST/ALT ratio for the different groups is illustrated in 
Figs 1a and 1b, showing a trend towards a higher value for patients 
with advanced fibrosis.
The AUC is illustrated in Fig. 2. The AUC was 0.61 with an AST/
ALT ratio of 0.8, having a sensitivity of 58% and specificity of 62%.
The mean APRI for the groups is illustrated in Figs 3a and 3b. The 
APRI was significantly higher in the advanced fibrosis group. The 
AUC for APRI is illustrated in Fig. 4. The AUC for APRI was 0.85 
with a cut-off of 0.98, giving a sensitivity of 75% and a specificity of 
86%. The mean NFS for the different groups is illustrated in Figs 5a 
and 5b, showing that the NFS was significantly lower in the advanced 
fibrosis group. The AUC for NFS is illustrated in Fig. 6. The AUC for 
NFS was 0.77 given at a cut-off of -1.31. The sensitivity and specificity 
for NFS was 76% and 69% respectively. The sensitivity, specificity, 
and positive and negative predictive values for APRI and NFS are 
compared in Table I. The positive predictive value for APRI was 54%, 
as opposed to 34% for NFS. The negative predictive value was 93% 
for APRI and 94% for NFS.
Discussion
Liver biopsy is regarded as the gold standard in the assessment of 
patients with NAFLD/NASH for advanced disease.22 However, liver 
Fig. 2. RUC for AST/ALT ratio and advanced fibrosis in NAFLD.
Fig. 1a. AST/ALT and association with severity of NAFLD.
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biopsy is an invasive procedure with potential complications, and 
sampling error can result in substantial misdiagnosis and staging 
inaccuracies. The major concern regarding liver biopsies is the lack 
of resources mainly owing to the large number of subjects affected by 
NAFLD. Approximately 60 - 90% of NAFLD-affected subjects have 
a benign form of the disease not requiring biopsy. The management 
of patients with NASH and no and minimal fibrosis does not differ, 
whereas patients with advanced forms of fibrosis must be identified 
for more intensive management.23 Improved methods are therefore 
required to identify patients at increased risk of severe liver disease 
without needing to perform a liver biopsy on all patients. Numerous 
test panels have been developed for non-invasive tests to diagnose 
advanced liver disease, of which only 4 have been evaluated in 
NAFLD.4 The group that investigated the BAAT score replaced this 
test by the FibroTest, which unfortunately is expensive and not widely 
available. The European Liver Fibrosis Study Group panel of ECM-
related components from which an algorithm was developed, is also 
not readily available and will be expensive, especially in developing 
countries. The NFS is an algorithm of 6 readily available laboratory 
and clinical variables including age, hyperglycaemia, BMI, platelet 
count, albumin, and AST/ALT ratio.19 By applying this model, almost 
75% of the 733 patients in this study could have avoided liver biopsy. 
Guha et al.20 determined that adding established simple markers to 
the ELF panel augmented the diagnostic performance.20 Wai et al.21 
validated the APRI score in patients with hepatitis C. APRI is a simple 
calculation of 2 laboratory variables –AST and platelets; this score can 
easily be used at the bedside or in an outpatient setting.
We attempted to validate APRI as a non-invasive marker of 
advanced fibrosis in subjects with NAFLD. By proving superior 
sensitivity and specificity of APRI compared with AST/ALT ratio 
Fig. 4. RUC for APRI and advanced fibrosis in NAFLD.
Fig. 6. RUC for NFS and advanced fibrosis in NAFLD.
Table I. Sensitivity, specificity, positive and negative predic-
tive value of APRI v. NFS
Value Sensitivity Specificity ppv npv
APRI 0.98 75% 86% 54% 94%
NFS -1.31 76% 69% 34% 93%
Fig. 3a. APRI and association with staging of NAFLD.
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and comparable sensitivity and specificity with NFS, the use of APRI 
is proposed as part of a simple, user-friendly and reliable algorithm 
to predict advanced fibrosis in subjects with NAFLD and thereby 
avoiding liver biopsies for patients with no or minimal fibrosis. Our 
study confirmed that ALT could neither differentiate between the 
stage of disease nor the grade of fibrosis. An AST/ALT ratio >0.8 
is an indicator of advanced disease. There was a strong tendency 
in the South African study towards subjects with advanced fibrosis 
having a higher ratio. However, the ROC curve for AST/ALT ratio 
and advanced fibrosis was only 0.61, indicating that the positive and 
negative predictive values were too low to make it a useful tool. APRI 
is a simple and inexpensive calculation making use of the AST value 
and platelet count. The formula has been validated in patients with 
hepatitis C but not in patients with NAFLD. Our study showed that 
the APRI for South African patients with advanced fibrosis differed 
significantly from that in patients with less severe disease. The ROC 
curve for an APRI of 0.98 and detection of advanced fibrosis was 
0.85, with positive and negative predictive values of 54% and 94% 
respectively.
Based on these findings, APRI is statistically superior to the AST/
ALT ratio for predicting advanced fibrosis, and has been validated for 
use in patients with NAFLD for the first time. The NFS was validated 
by Angulo et al.19 for use in patients with NAFLD. Our results were 
similar by showing that subjects with advanced fibrosis had a NFS 
significantly different from that in subjects without advanced fibrosis. 
The AUC curve for the NFS of -1.31 and prediction of advanced 
fibrosis was 0.765. The positive and negative predictive values were 
34% and 93% respectively.
This study confirmed that APRI is useful for detecting advanced 
fibrosis in subjects with NAFLD, and compares favourably with NFS 
to predict advanced fibrosis. However, APRI is easier to use than 
NFS, is inexpensive and can be used in an outpatient setting and at 
the bedside. The positive predictive values of these 2 tests were low. 
According to Guha et al.,20 the addition of the ELF panel to the NFS 
increased the positive predictive value for advanced fibrosis.
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Writing poetry;
Profoundly changing with it –
Listening to me.
Haiku: Peter Folb
